Article
Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.
Nature cancer - 1 Feb 2026
Vassy Jason L, Dornisch Anna M, Karunamuni Roshan, Gatzen Michael, Kachulis Christopher J, Lennon Niall J, Brunette Charles A, Danowski Morgan E, Hauger Richard L, Garraway Isla P, Kibel Adam S, Lee Kyung M, Lynch Julie A, Maxwell Kara N, Ratner Dmitry, Rose Brent S, Teerlink Craig C, Xu George J, Hofherr Sean E, Lafferty Katherine A, Larkin Katie, Malolepsza Edyta, Patterson Candace J, Toledo Diana M, Donovan Jenny L, Hamdy Freddie C, Martin Richard M, Neal David E, Turner Emma L, Andreassen Ole A, Dale Anders M, Mills Ian G, Abraham Aswin, Batra Jyotsna, Clements Judith, Cussenot Olivier, Cybulski Cezary, Eeles Rosalind A, Fowke Jay H, Grindedal Eli Marie, Grönberg Henrik, Hamilton Robert J, Lim Jasmine, Lu Yong-Jie, MacInnis Robert J, Maier Christiane, Mucci Lorelei A, Multigner Luc, Neuhausen Susan L, Nielsen Sune F, Parent Marie-Élise, Park Jong Y, Petrovics Gyorgy, Plym Anna, Razack Azad, Rosenstein Barry S, Schleutker Johanna, Sørensen Karina Dalsgaard, Townsend Paul A, Travis Ruth C, Vega Ana, West Catharine M L, Wiklund Fredrik, Zheng Wei, Seibert Tyler M
Abstract excerpt
Precision healthcare aims to tailor disease prevention and early detection to individual risk. Prostate cancer screening may benefit from genomics-informed approaches. We developed and validated the P-CARE model, a prostate cancer risk prediction tool combining a polygenic score, family history and genetic ancestry, using data from over 585,000 male participants in the Million Veteran Program. The model was...
Read the complete abstract on PubMed